| 1 |
NCT03478228 |
Completed
New |
Multi-Sensory Training and Wrist Fractures |
|
- Other: Multi-Sensory Training
|
Interventional |
Not Applicable |
- Landspitali University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sensory Organization Test (SOT)
|
150 |
All |
50 Years to 75 Years (Adult, Senior) |
NCT03478228 |
2013 16 ÓB/eí |
|
May 15, 2015 |
May 25, 2016 |
May 25, 2016 |
March 27, 2018 |
March 27, 2018 |
|
- University of Iceland
Reykjavik, Iceland
|
| 2 |
NCT03327597 |
Recruiting |
Iceland Screens, Treats or Prevents Multiple Myeloma |
- Monoclonal Gammopathy of Undetermined Significance
|
- Other: Clinical follow-up 1
- Other: QoL questionnaire
- Other: Standard follow-up or treatment.
- (and 3 more...)
|
Interventional |
Not Applicable |
- University of Iceland
- Landspitali University Hospital
- Union for International Cancer Control
- (and 7 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Screening
|
- Overall survival
- Cause specific survival
- Quality of life (QoL)
- Cost-effectiveness of screening for MGUS
|
78000 |
All |
40 Years and older (Adult, Senior) |
NCT03327597 |
UI-2017-MGUS |
iStopMM |
September 1, 2016 |
September 1, 2021 |
September 1, 2021 |
October 31, 2017 |
November 17, 2017 |
|
- University of Iceland
Reykjavík, Iceland
|
| 3 |
NCT02752633 |
Completed
Has Results |
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion |
- Adenine Phosphoribosyltransferase Deficiency
|
- Drug: Allopurinol
- Drug: Febuxostat
|
Interventional |
Phase 4 |
- Landspitali University Hospital
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Urinary 2,8-dihydroxyadenine Excretion
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT02752633 |
RDCRN Protocol #6412
2013-000975-33
U54DK083908 |
|
May 2013 |
May 2015 |
May 2015 |
April 27, 2016 |
December 27, 2017 |
December 27, 2017 |
- Landspitali - The National University Hospital of Iceland
Reykjavik, Iceland
|
| 4 |
NCT02705664 |
Completed |
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% |
|
- Drug: Loceryl Nail Lacquer
- Drug: Urea Ointment
- Drug: Bifonazole Cream
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- % adherent subjects with applications
- % adherent subjects with nail preparation
- % Subjects satisfied to very satisfied with each study treatment at week 7
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT02705664 |
RD.03.SPR.105078 |
OPEN |
January 2016 |
September 2016 |
September 2016 |
March 10, 2016 |
September 16, 2016 |
|
- Principal Investigator
Reykjavik, Iceland
|
| 5 |
NCT02682212 |
Active, not recruiting |
Obstetric Perineal Trauma and Physiotherapy |
|
- Other: Physiotherapy intervention
|
Interventional |
Not Applicable |
- Landspitali University Hospital
- University of Iceland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Urinary incontinence rates measured by scores on the Australian Female PelvicFloor questionnaire
- Fecal/flatal incontinence measured by scores on the Australian Female PelvicFloor questionnaire
- Sexual dysfunction measured by scores on the Australian Female PelvicFloor questionnaire
- Quality of life measured by scores on the Australian Female PelvicFloor questionnaire
|
84 |
Female |
18 Years and older (Adult, Senior) |
NCT02682212 |
LSH-15-001 |
|
March 16, 2016 |
July 2018 |
December 2018 |
February 15, 2016 |
November 14, 2017 |
|
- Tap, Physical Therapy Clinic
Kopavogur, Iceland
|
| 6 |
NCT02647879 |
Recruiting |
Treatment as Prevention for Hepatitis C in Iceland |
|
|
Observational |
|
- Landspitali University Hospital
- SAA -National Center of Addiction Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of transmission of HCV in Iceland
- Incidence of cirrhosis and hepatocellular carcinoma in Iceland
- Sustained virological response rate (SVR) to treatment with antiviral agents as measured by negative HCV RNA 12 weeks post treatment
- Reinfection rate as measured by new infections diagnosed in patients who were previously treated and achieved SVR
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT02647879 |
LSH-15-003 |
TraPHepC |
January 2016 |
December 2018 |
May 2031 |
January 6, 2016 |
March 28, 2017 |
|
- Landspitali
Reykjavik, Iceland
|
| 7 |
NCT02321098 |
Completed |
Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish |
|
- Drug: Loceryl Nail Lacquer
- Drug: Loceryl Nail Lacquer follow up period
- Other: Cosmetic varnish
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Measurement of diameter of zones of inhibition (mm) produced by residual drug in toenails
- Presence/absence of Dermatophytes in nail samples culture
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02321098 |
RD.03.SPR29106
2013-000544-26 |
COOL |
February 2014 |
January 2016 |
January 2016 |
December 22, 2014 |
February 11, 2016 |
|
- Principal Investigator
Reykjavik, Iceland
|
| 8 |
NCT02301273 |
Completed |
Being Awake, Upright and Moving as the Basis for Early ICU Physiotherapy |
|
- Other: Usual Physiotherapy
- Other: Enhanced Physiotherapy
|
Interventional |
Not Applicable |
- Landspitali University Hospital
- University of Iceland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Length of ICU and hospital stay
- Physical Function
- Physical function
- Health Related Quality of Life
|
60 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02301273 |
16.2011 |
|
November 2011 |
November 2015 |
November 2015 |
November 25, 2014 |
November 30, 2015 |
|
- Landspítali University Hospital
Reykjavík, Iceland
|
| 9 |
NCT02251496 |
Active, not recruiting |
COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks. |
|
- Other: In between meals snacks (Snacks-group)
- Other: Oral nutrition supplement (ONS-group)
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Weight changes
- Health related quality of life (HRQoL)
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT02251496 |
COPD-141316051 |
COPD |
September 2014 |
December 2017 |
December 2017 |
September 29, 2014 |
May 3, 2017 |
|
- The Department of Thoracic Medicine at Landspítali
Reykjavík, Iceland
|
| 10 |
NCT02236455 |
Completed |
Effects of Complementary Therapies Delivered Via Mobile Technologies |
- Acute Pain
- Anxiety
- Self Efficacy
|
- Behavioral: Audio Relaxation Technique
- Behavioral: Medical Music Intervention
- Behavioral: Nature Therapy without Music
- Behavioral: Nature Therapy with Music
|
Interventional |
Not Applicable |
- University of San Francisco
- Fulbright
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change from baseline state anxiety via the State Trait Anxiety Scale (STAI)
- Change in baseline pain level using the Numeric Rating Scale (NRS)
|
105 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02236455 |
S5862 |
|
March 2012 |
December 2012 |
December 2012 |
September 10, 2014 |
September 10, 2014 |
|
- Landspítala
Reykjavik, Iceland
|
| 11 |
NCT01917591 |
Completed |
Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study |
- Punch Biopsy Wounds
- Healing Times
|
- Device: Punch biopsies treated with MariGen Wound ECM dressing
- Device: Punch biopsies treated with Oasis ECM dressing
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- wound healing
- Autoimmune investigations
- Incidence of erythema
- (and 2 more...)
|
81 |
All |
18 Years and older (Adult, Senior) |
NCT01917591 |
KS-0070 |
|
January 2013 |
June 2013 |
July 2013 |
August 6, 2013 |
March 3, 2017 |
|
- Læknastofur Skipholti
Reykjavik, Iceland
|
| 12 |
NCT01565239 |
Completed |
Fiix-prothrombin Time for Monitoring Warfarin |
- Thromboembolism
- Arterial
- Venous
|
- Device: Fiix prothrombin time
|
Interventional |
Phase 2 |
- Landspitali University Hospital
- University of Rochester
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Thromboembolic events
- Major hemorrhage
- Monitoring test frequency and time spent within target range
|
1156 |
All |
18 Years and older (Adult, Senior) |
NCT01565239 |
Landspitali-1 |
Fiix |
March 2012 |
February 2014 |
February 2014 |
March 28, 2012 |
September 9, 2014 |
|
- Landspitali University Hospital
Reykjavik, N.a., Iceland
|
| 13 |
NCT01391741 |
Completed |
The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD) |
|
- Other: Visual Cues
- Other: Walking without visual cues
|
Interventional |
Phase 3 |
- University of Iceland
- The Icelandic Parkinson´s Association.
- Icelandic Physiotherapy Association
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Step Length
- Change in Gait Velocity
- Change in Stride Time Variability
- Change in Timed Up & Go (seconds)
|
26 |
All |
up to 79 Years (Child, Adult, Senior) |
NCT01391741 |
123SmOkE |
|
April 2008 |
September 2008 |
September 2008 |
July 12, 2011 |
July 12, 2011 |
|
- Reykjalundur Rehabilitation Center
Mosfellsbaer, Iceland
|
| 14 |
NCT01348581 |
Completed |
Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing |
- Pressure Ulcers
- Venous Ulcers
- Diabetic Ulcers
- (and 2 more...)
|
- Device: Marigen Wound Dressing
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Wound healing
- Wound granulation
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT01348581 |
KERECIS-10-106-S1
MW-ECM |
|
November 2010 |
December 2012 |
January 1, 2013 |
May 5, 2011 |
March 3, 2017 |
|
- National University Hospital
Reykjavik, Iceland
|
| 15 |
NCT01322568 |
Completed |
Research on Aging Project in Iceland: Second Stage |
- Atherosclerosis
- Osteoporosis
- Obesity
- (and 3 more...)
|
|
Observational |
|
- National Institute on Aging (NIA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
5764 |
All |
32 Years to 60 Years (Adult) |
NCT01322568 |
999903319
03-AG-N319 |
|
January 31, 2003 |
|
February 11, 2014 |
March 24, 2011 |
April 17, 2018 |
|
- Icelandic Heart Association Research Institute
Kopavogur, Iceland
|
| 16 |
NCT01100853 |
Completed
Has Results |
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland |
|
- Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
|
Interventional |
Phase 3 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
- Society of Alcoholism and other Addictions
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number Negative Urines (Proportion Negative Urines)
- Number Negative Urines (Proportion Negative Urines) Amphetamine
- Amphetamine Craving Scale
- (and 3 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01100853 |
811095
P50DA012756
2009-013647-10 |
|
May 2010 |
February 2013 |
February 2013 |
April 9, 2010 |
March 6, 2018 |
January 13, 2014 |
- SAA National Center of Addiction Medicine, Vogur Hospital
Storhofda 45, Reykjavík, Iceland
|
| 17 |
NCT01074879 |
Completed |
Protein Ingestion and Resistance Exercise in Elderly |
|
- Dietary Supplement: Whey protein
- Dietary Supplement: Milk protein
- Dietary Supplement: Carbohydrates
|
Interventional |
Not Applicable |
- University of Iceland
- Landspitali University Hospital Research Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
|
220 |
All |
65 Years and older (Adult, Senior) |
NCT01074879 |
071323007 |
IceProQualita |
August 2008 |
December 2009 |
December 2009 |
February 24, 2010 |
February 24, 2010 |
|
- Unit for Nutrition Research
Reykjavik, Iceland
|
| 18 |
NCT00853749 |
Completed
Has Results |
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine |
- Invasive Pneumococcal Disease
|
- Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
- Procedure: Blood draw
|
Interventional |
Phase 3 |
- Wyeth is now a wholly owned subsidiary of Pfizer
- Pfizer
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After Vaccination
- Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination
- Antibody Response Measured 1 Month After Vaccination (Avidity Assay)
- Antibody Response Measured 1 Month After Vaccination (OPA)
|
89 |
All |
5 Years to 8 Years (Child) |
NCT00853749 |
6096A1-3013
B1851012 |
REPLAY |
May 2009 |
August 2010 |
August 2010 |
March 2, 2009 |
January 5, 2011 |
January 5, 2011 |
- Pfizer Investigational Site
Reykjavik, Iceland
|
| 19 |
NCT00346008 |
Completed |
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members |
|
- Genetic: mutation analysis
- Other: high performance liquid chromatography
- Other: laboratory biomarker analysis
- Other: questionnaire administration
|
Observational |
|
- Iceland Genomics Corporation
- National Cancer Institute (NCI)
|
Industry / NIH |
|
- Feasibility to identify melanoma
- Feasibility to detect mutation
- Ability to create datasets
|
2500 |
All |
Child, Adult, Senior |
NCT00346008 |
NBCI-03-033-CM
NCI-06-C-N026
CDR0000551606
NBCI-01-087-CM
999906026 |
|
October 2005 |
December 2008 |
February 2009 |
June 29, 2006 |
May 30, 2013 |
|
- Iceland Genomics Corporation
Reykjavik, Iceland
|
| 20 |
NCT03272516 |
Recruiting |
Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients |
|
- Behavioral: Mindfulness based cognitive therapy (MBCT)
- Other: Treatment as usual (TAU)
|
Interventional |
Not Applicable |
- University of Iceland
- University of Aarhus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Health Services Research
|
- Symptoms of depression measured with the PHQ-9 questionnaire
- Symptoms of anxiety measured with the GAD-7 questionnaire
- Subjective well-being measured with the SWEMWBS questionnaire
- (and 2 more...)
|
165 |
All |
18 Years to 67 Years (Adult, Senior) |
NCT03272516 |
UI-2017-MBCT. |
|
September 12, 2017 |
October 10, 2019 |
October 10, 2019 |
September 5, 2017 |
September 19, 2017 |
|
- Heilsugæslan Grafarvogi
Reykjavík, Grafarvogur, Iceland - Heilsugæslan Miðbæ
Reykjavík, Iceland
|
| 21 |
NCT03176732 |
Recruiting |
Mechanisms for Individual Differences in Hypertension in Obstructive Sleep |
- Sleep Apnea, Obstructive
- Hypertension
|
- Device: Positive Airway Pressure
|
Observational |
|
- University of Pennsylvania
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Nocturnal mean arterial blood pressure (nMAP)
- Oxidative stress
- Sympathetic activity
|
200 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03176732 |
823172
P01HL094307-06A1 |
PISA-BP |
June 6, 2017 |
September 30, 2021 |
September 30, 2021 |
June 5, 2017 |
June 8, 2017 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States - University of Iceland
Reykjavík, Iceland
|
| 22 |
NCT02124395 |
Recruiting |
Health-related Quality of Life in Rare Kidney Stone |
- Primary Hyperoxaluria
- Cystinuria
- Adenine Phosphoribosyl Transferase Deficiency
- Dent Disease
|
- Other: Health-related Quality of Life in Rare Kidney Stone Questionnaire
|
Observational |
|
- New York University School of Medicine
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Assessment of HRQoL in patients with rare kidney stones
|
320 |
All |
5 Years and older (Child, Adult, Senior) |
NCT02124395 |
13-00968
1U54DK083908-01 |
|
August 2013 |
September 2018 |
September 2018 |
April 28, 2014 |
November 22, 2017 |
|
- Primary Hyperoxaluria and Dent Disease Registry - Mayo Clinic
Rochester, Minnesota, United States - New York University School of Medicine - Cystinuria Registry
New York, New York, United States - APRT Registry - Landspitali Universtiy Hospital
Reykjavik, Iceland
|
| 23 |
NCT00449553 |
Completed |
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. |
|
- Drug: Pioglitazone and sulphonylurea
- Drug: Pioglitazone and metformin
|
Observational |
|
- Takeda
- Eli Lilly and Company
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change from baseline in glycosylated hemoglobin.
- Change from baseline in Clinical Laboratory Tests (alanine transaminase, hematocrit and hemoglobin).
- Change from baseline in Body Weight.
- (and 4 more...)
|
326 |
All |
18 Years and older (Adult, Senior) |
NCT00449553 |
H6E-CP-GLAR
U1111-1114-2473 |
|
June 2001 |
September 2003 |
September 2003 |
March 20, 2007 |
February 28, 2012 |
|
- Multiple, Denmark
- Multiple, Iceland
- Multiple, Norway
- Multiple, Sweden
|
| 24 |
NCT01088217 |
Recruiting |
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) |
- Idiopathic Pulmonary Fibrosis
- Familial Pulmonary Fibrosis
- Idiopathic Interstitial Pneumonia
- Familial Interstitial Pneumonia
|
|
Observational |
|
- National Jewish Health
- University of Colorado, Denver
- Vanderbilt University
- Landspitali University Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Cross-Sectional
|
- Identify a group of genetic loci that play a role in the development of familial interstitial pneumonia and idiopathic interstitial pneumonia.
- Develop biomarkers using proteomic and genomic approaches that will facilitate establishing the diagnosis and prognosis of both familial and sporadic forms of idiopathic interstitial pneumonia (IIP).
|
8000 |
All |
Child, Adult, Senior |
NCT01088217 |
2R01HL097163 |
GWAS |
July 2008 |
June 2019 |
June 2019 |
March 17, 2010 |
March 29, 2018 |
|
- University of Colorado Denver
Aurora, Colorado, United States - National Jewish Health and University of Colorado Denver
Denver, Colorado, United States - Vanderbilt University
Nashville, Tennessee, United States - Landspitali University Hospital
Reykjavik, Iceland
|
| 25 |
NCT00697242 |
Completed |
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults |
|
- Biological: Engerix™-B
- Biological: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Anti-hepatitis B surface antigen (HBs) antibody concentrations
- Anti-pre-S1 antibody concentrations
- Anti-HBs antibody concentrations
- (and 4 more...)
|
362 |
All |
50 Years to 70 Years (Adult, Senior) |
NCT00697242 |
208129/009 |
|
January 1994 |
November 1995 |
November 1995 |
June 13, 2008 |
June 13, 2008 |
|
- GSK Clinical Trials Call Center
Wien, Austria - GSK Clinical Trials Call Center
Gent, Belgium - GSK Clinical Trials Call Center
Hvidovre, Denmark - GSK Clinical Trials Call Center
Reykjavik, Iceland
|
| 26 |
NCT00588562 |
Recruiting |
Rare Kidney Stone Consortium Patient Registry |
- Primary Hyperoxaluria
- Dent Disease
- Cystinuria
- APRT Deficiency
|
|
Observational |
|
- Mayo Clinic
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Oxalosis and Hyperoxaluria Foundation (OHF)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
- Establish and expand registries and collaborate with patient organizations for the rapid dissemination of knowledge
- Improved understanding of symptoms and progression of four major diseases of hereditary nephrolithiasis.
|
730 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT00588562 |
11-001702
1U54DK083908-01 |
RKSC |
July 2003 |
June 2019 |
June 2019 |
January 8, 2008 |
August 4, 2017 |
|
- Dent Disease Registry -Mayo Clinic
Rochester, Minnesota, United States - Primary Hyperoxaluria Registry - Mayo Clinic
Rochester, Minnesota, United States - Cystinuria Registry - New York University
New York, New York, United States - APRT Registry - Landspitali Universtiy Hospital
Reykjavik, Iceland
|
| 27 |
NCT01305655 |
Completed
Has Results |
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL |
- Acute Lymphoblastic Leukemia (ALL)
|
|
Interventional |
Phase 3 |
- Nordic Society for Pediatric Hematology and Oncology
- Lund University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity, Mucositis, MTX Elimination Time and Permanent Kidney Damage.
- Evaluate Time at Hospital and Health Costs
|
47 |
All |
1 Year to 18 Years (Child, Adult) |
NCT01305655 |
NOPHO2008CPG2 |
NOPHOCPG2 |
July 2008 |
December 2014 |
December 2014 |
March 1, 2011 |
February 3, 2017 |
February 3, 2017 |
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University of Reykjavik
Reykjavik, Iceland - (and 2 more...)
|
| 28 |
NCT00991744 |
Suspended |
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) |
- Acute Lymphoblastic Leukemia
|
- Drug: Liposomal cytarabine
- Drug: Intrathecal triple
|
Interventional |
Phase 3 |
- Nordic Society for Pediatric Hematology and Oncology
- Oulu University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of leukemia relapses in the central nervous system
- Neurological toxicity
|
100 |
All |
1 Year to 18 Years (Child, Adult) |
NCT00991744 |
NOPHOALL2008-DepoCyte |
|
January 2009 |
December 2018 |
December 2018 |
October 8, 2009 |
October 10, 2012 |
|
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University of Reykjavik, Iceland
Reykjavik, Iceland - (and 2 more...)
|
| 29 |
NCT01327846 |
Active, not recruiting |
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) |
|
- Drug: Canakinumab
- Drug: Placebo
- Drug: Standard of care
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Main:Time to first occurrence of major adverse cardiovascular event, which is a composite of CV death, non-fatal MI, and stroke.
- Substudy 1; Change from baseline in carotid plaque burden in the bifurcation region of the index carotid artery
- Substudy 2; Change from baseline of the insulin secretion rate (ISR) relative to glucose 0-30 min defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 averaged across the yearly visits.
- (and 12 more...)
|
10061 |
All |
18 Years and older (Adult, Senior) |
NCT01327846 |
CACZ885M2301
2010-022970-14 |
CANTOS |
April 11, 2011 |
March 28, 2017 |
March 2, 2020 |
April 4, 2011 |
March 20, 2018 |
|
- Novartis Investigative Site
Athens, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - (and 1130 more...)
|
| 30 |
NCT01035255 |
Terminated
Has Results |
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure |
- Heart Failure With Reduced Ejection Fraction
|
- Drug: LCZ696 200 mg BID
- Drug: Enalapril 10 mg BID
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
- Number of Patients - All-cause Mortality
- Number of Patients Reported With Adjudicated Primary Causes of Death
- (and 3 more...)
|
8442 |
All |
18 Years and older (Adult, Senior) |
NCT01035255 |
CLCZ696B2314
2009-015834-31 |
PARADIGM-HF |
December 2009 |
May 2014 |
May 2014 |
December 18, 2009 |
August 15, 2016 |
September 7, 2015 |
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Huntsville, Alabama, United States - (and 1027 more...)
|
| 31 |
NCT00224484 |
Completed
Has Results |
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old |
|
- Biological: GSK208141
- Biological: HavrixTM (investigational formulation)
- Biological: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Number of Subjects With Serious Adverse Events (SAEs)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
- (and 7 more...)
|
5960 |
Female |
10 Years to 17 Years (Child) |
NCT00224484 |
208141/040 |
|
April 2004 |
July 2007 |
July 2007 |
September 23, 2005 |
April 10, 2017 |
April 10, 2017 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Chandler, Arizona, United States - (and 149 more...)
|
| 32 |
NCT02900378 |
Recruiting |
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure |
- Chronic Heart Failure With Reduced Ejection Fraction
|
- Drug: LCZ696 (sacubitril/valsartan)
- Drug: Placebo to LCZ696 (sacubitril/valsartan)
- Drug: Enalapril
- Drug: Placebo to enalapril
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in mean daily non-sedentary daytime activity between baseline and end of study
- Percentage of patients with improved symptoms of heart failure as assessed by Patient's Global Assessment
- Change from baseline in mean daily non-sedentary daytime activity in weekly and two-weekly intervals
- (and 7 more...)
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02900378 |
CLCZ696B3301
2016-003085-32 |
OUTSTEP-HF |
December 20, 2016 |
July 5, 2018 |
July 5, 2018 |
September 14, 2016 |
November 17, 2017 |
|
- Novartis Investigative Site
Dendermonde, Belgium - Novartis Investigative Site
Edegem, Belgium - Novartis Investigative Site
Geel, Belgium - (and 130 more...)
|
| 33 |
NCT01764633 |
Completed
Has Results |
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk |
|
- Biological: Evolocumab
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization
- Time to Cardiovascular Death, Myocardial Infarction, or Stroke
- Time to Cardiovascular Death
- (and 6 more...)
|
27564 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT01764633 |
20110118
2014/01/004324
2012-001398-97 |
FOURIER |
February 8, 2013 |
November 11, 2016 |
November 11, 2016 |
January 9, 2013 |
February 15, 2018 |
February 15, 2018 |
- Research Site
Birmingham, Alabama, United States - Research Site
Birmingham, Alabama, United States - Research Site
Huntsville, Alabama, United States - (and 1284 more...)
|
| 34 |
NCT01369329 |
Completed
Has Results |
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) |
- Crohn's Disease
- IBD
- Colitis
- Inflammatory Bowel Disease
|
- Drug: Group 2 ustekinumab 130 mg
- Drug: Group 3: ustekinumab approximately 6 mg/kg
- Drug: Group 1: Placebo
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Clinical Response at Week 6
- Number of Participants in Clinical Remission at Week 8
- Number of Participants in Clinical Response at Week 8
- (and 2 more...)
|
769 |
All |
18 Years and older (Adult, Senior) |
NCT01369329 |
CR018415
CNTO1275CRD3001
2010-022758-18 |
|
July 2011 |
June 2013 |
July 2013 |
June 8, 2011 |
December 7, 2016 |
December 7, 2016 |
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- La Jolla, California, United States
- (and 174 more...)
|
| 35 |
NCT00268216 |
Completed |
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- All cause mortality at 3 years
- Rate of moderate and severe COPD exacerbations and health status assessed by the St. George's Respiratory Questionnaire.
|
6228 |
All |
40 Years to 80 Years (Adult, Senior) |
NCT00268216 |
SCO30003 |
|
September 2000 |
November 2005 |
November 2005 |
December 22, 2005 |
January 20, 2017 |
|
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - (and 456 more...)
|
| 36 |
NCT00252824 |
Completed |
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma |
|
- Drug: Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to first severe asthma exacerbation
- Number of asthma exacerbations
- Mean use of as-needed medication
- (and 5 more...)
|
1000 |
All |
12 Years and older (Child, Adult, Senior) |
NCT00252824 |
D5890L00014
STYLE |
|
July 2005 |
|
December 2006 |
November 15, 2005 |
January 24, 2011 |
|
- Research Site
Quillota, Chile - Research Site
Valparaiso, Chile - Researh Site
Dubrovnik, Croatia - (and 50 more...)
|
| 37 |
NCT00251914 |
Completed |
Nexium Dyspepsia/AST |
- Gastrointestinal Disease
- Signs and Symptoms, Digestive
- Dyspepsia
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary outcome is whether the patient is a responder or not after 8 weeks treatment.
- The primary efficacy outcome is based on symptom score recorded daily during the study in a patient diary.
- The patient will judge their symptoms of pain or burning centered in the upper abdomen on a four-graded scale (none, mild, moderate or severe).
- (and 3 more...)
|
1500 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00251914 |
SD-NED-0021
D9610C00021 |
|
December 2002 |
January 2005 |
January 2005 |
November 11, 2005 |
January 24, 2011 |
|
- Research Site
Buenos Aires, Argentina - Research Site
Mendoza, Argentina - Research Site
Rosario, Argentina - (and 214 more...)
|
| 38 |
NCT00159835 |
Completed |
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD |
|
- Drug: atorvastatin
- Drug: simvastatin
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest
- 1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality
|
8600 |
All |
up to 80 Years (Child, Adult, Senior) |
NCT00159835 |
ATV-N-98-001
A2581145 |
IDEAL |
February 1999 |
|
March 2005 |
September 12, 2005 |
April 22, 2015 |
|
- Pfizer Investigational Site
Arhus C, Denmark - Pfizer Investigational Site
Copenhagen, Denmark - Pfizer Investigational Site
Esbjerg, Denmark - (and 191 more...)
|
| 39 |
NCT02563717 |
Recruiting |
Comparison Of Respiratory Support After Delivery on Infants Born Before 28 Weeks Gestational Age |
- Respiration; Insufficient or Poor, Newborn
- Infant, Premature, Diseases
|
- Device: T-piece used for respiratory support (several manufacturers)
- Device: New system used for respiratory support
|
Interventional |
Not Applicable |
- Baldvin Jonsson
- Karolinska Institutet
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Delivery room intubation or death
- Time to primary outcome (intubation or death)
- Death
- (and 4 more...)
|
250 |
All |
Child, Adult, Senior |
NCT02563717 |
2015/927-31/4 |
CORSAD |
March 2016 |
December 2018 |
December 2018 |
September 30, 2015 |
December 13, 2017 |
|
- Department of neonatology, University Hospital of Iceland
Reykjavík, Iceland - Neonatal Unit, Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania - Stavanger University Hospital, Department of Pediatrics
Stavanger, Norway - (and 3 more...)
|
| 40 |
NCT00819351 |
Completed |
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase |
- Acute Lymphoblastic Leukemia
|
- Drug: PEG Asparaginase at six weeks interval
- Drug: PEG Asparaginase at two weeks interval
|
Interventional |
Phase 3 |
- Rigshospitalet, Denmark
- Nordic Society for Pediatric Hematology and Oncology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival
- Secondary Outcome Measures are toxicity (special focus on thrombosis, pancreatitis, and allergic reactions), the formation of silent antibodies, and the influence of antibody production on the EFS.
|
650 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00819351 |
NOPHO ALL2008 PEG Asparaginase |
|
January 1, 2009 |
March 2, 2016 |
March 2, 2016 |
January 9, 2009 |
April 21, 2017 |
|
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University Hospital Reykjavik, Iceland
Reykjavik, Iceland - (and 3 more...)
|
| 41 |
NCT00816049 |
Completed |
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy |
- Acute Lymphoblastic Leukemia
|
- Drug: 6MPindividualized
- Drug: 6MPfixed
|
Interventional |
Phase 3 |
- Rigshospitalet, Denmark
- Nordic Society for Pediatric Hematology and Oncology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Fraction of patients that become MRD-negative at treatment days 85 and/or 92 (end-of-consolidation) and event-free survival. MRD is measured either by Flow-cytometry (for PreB-ALL patients) or PCR for clonal generearrangements(for T-ALL patients)
- Toxicity of treatment, degree of myelo-, hepato- and renal toxicity; and development of asparaginase antibodies.
|
775 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00816049 |
NOPHO ALL2008 consolidation |
ALL2008con |
January 2009 |
March 2, 2016 |
March 2, 2016 |
December 31, 2008 |
April 21, 2017 |
|
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University Hospital
Reykjavik, Iceland - (and 3 more...)
|
| 42 |
NCT01025804 |
Completed |
Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06 |
|
|
Observational |
|
- Aarhus University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- pharmacokinetics, antibody formation, side effects
|
15 |
All |
up to 1 Year (Child) |
NCT01025804 |
Interfant-06, NOPHO
register identifier |
|
December 2009 |
December 2014 |
December 2015 |
December 4, 2009 |
March 4, 2016 |
|
- Aarhus University Hospital, Department of Pediatrics Skejby Hospital
Aarhus, Aarhus N, Denmark - Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - (and 3 more...)
|
| 43 |
NCT01587378 |
Completed |
Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome |
- Pregnancy
- Polycystic Ovary Syndrome
|
- Drug: Metformin
- Drug: placebo
|
Interventional |
Not Applicable |
- Norwegian University of Science and Technology
- Vestre Viken Hospital Trust
- Landspitali University Hospital
- (and 11 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- combined incidence of late miscarriages and preterm births
- NICU admissions and total number of days in NICU/baby
- number of patients hospitalized
- (and 4 more...)
|
489 |
Female |
18 Years to 45 Years (Adult) |
NCT01587378 |
2011/1434
2011-002203-15 |
PregMet2 |
October 2012 |
August 2017 |
October 1, 2017 |
April 30, 2012 |
October 6, 2017 |
|
- Landspital University Hospital
Reykjavik, Iceland - Haukeland University Hospital
Bergen, Norway - Nordlandssykehuset HF
Bodø, Norway - (and 10 more...)
|
| 44 |
NCT02166736 |
Completed |
Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome |
- Angina Pectoris
- Acute Myocardial Infarction
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- All cause death, non-fatal Myocardial infarction (MI), Unplanned revascularization
- All cause death
- Non-fatal MI
- (and 6 more...)
|
2037 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02166736 |
U-2013-044 |
iFR Swedeheart |
May 2014 |
October 2015 |
December 2016 |
June 18, 2014 |
January 12, 2017 |
|
- Skejby University Hospital
Aarhus, Denmark - Reykjavik University Hospital
Reykjavik, Iceland - Sahlgrenska University Hospital
Göteborg, Sweden - (and 11 more...)
|
| 45 |
NCT01093404 |
Completed |
Thrombus Aspiration in Myocardial Infarction |
- Acute Myocardial Infarction
|
- Procedure: Thrombus aspiration
|
Interventional |
Not Applicable |
- Region Örebro County
- Uppsala University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- All-cause death
- Time to re-hospitalization with nonfatal reinfarction, heart failure and target vessel revascularization
- Time to all-cause death or new myocardial infarction (first occurring) or in hospital treatment for heart failure
- (and 3 more...)
|
7243 |
All |
18 Years and older (Adult, Senior) |
NCT01093404 |
SCAAR-001 |
TASTE |
July 2010 |
March 2013 |
August 2013 |
March 25, 2010 |
July 11, 2016 |
|
- Skejby Hospital, Aarhus University Hospital
Aarhus, Denmark - Landspitali University Hospital
Reykjavik, Iceland - Södra Älvsborgs sjukhus
Borås, Sweden - (and 26 more...)
|
| 46 |
NCT02382718 |
Completed |
FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy |
|
- Biological: FAST fish mCyp c 1
- Biological: Placebo
|
Interventional |
Phase 2 |
- George Stavroulakis
- Hospital San Carlos, Madrid
- Odense University Hospital OUH Denmark
- (and 8 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Efficacy of subcutaneous immunotherapy with mCyp c 1 for the treatment of fish allergy (change from baseline in the threshold of fish protein that induces an allergic reaction)
- Safety (recording of adverse events)- Number of participants with adverse events and recording of the nature of adverse events
- Severity of reaction in food challenge
- (and 3 more...)
|
45 |
All |
18 Years to 65 Years (Adult) |
NCT02382718 |
FAST2015 |
FASTIIb |
October 2015 |
February 2017 |
April 2017 |
March 9, 2015 |
June 12, 2017 |
|
- National University Hospital NUHD Denmark
Gentofte, Denmark - Odense University Hospital OUH Denmark
Odense, Denmark - Sotiria General Hospital for the Diseases of the Thorax
Athens, Greece - (and 6 more...)
|
| 47 |
NCT02523339 |
Recruiting |
Study of Retinal Oxygenation in Central Retinal Vein Occlusion |
|
|
Observational |
|
- University of Iceland
- University Hospital, Basel, Switzerland
- Aston University
- (and 6 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Retinal vessel oxygen saturation
- Visual acuity
- Central retinal thickness
- Presence or absence of ocular neovascularisation
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT02523339 |
UI-CRVO-2015 |
|
October 2014 |
December 2017 |
|
August 14, 2015 |
May 3, 2017 |
|
- Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria - Department of Ophthalmology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc
Olomouc, Czechia - Aarhus University. Department of Clinical Medicine - The Department of Ophthalmology
Aarhus, Denmark - (and 5 more...)
|
| 48 |
NCT00883792 |
Active, not recruiting |
The Northern-European Initiative on Colorectal Cancer |
|
|
Interventional |
Phase 3 |
- Oslo University Hospital
- Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
- Erasmus Medical Center
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence
- CRC mortality and CRC incidence of screening attendees compared to the control group and non-attendees
- Mortality from all causes
|
95000 |
All |
55 Years to 64 Years (Adult) |
NCT00883792 |
NordICC |
NordICC |
May 2009 |
June 2026 |
July 2036 |
April 20, 2009 |
June 19, 2017 |
|
- Harvard School of Public Health
Boston, Massachusetts, United States - Memorial Sloan-Kettering Cancer Center
New York, New York, United States - Landspitali University Hospital
Reykjavik, Iceland - (and 4 more...)
|
| 49 |
NCT00777946 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone |
|
- Drug: Aliskiren 300 mg
- Drug: Aliskiren/Amlodipine 300/5 mg
- Drug: Aliskiren/Amlodipine 300/10 mg
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)
- Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)
- Number of Participants With Serious Adverse Events and Adverse Events
- (and 3 more...)
|
818 |
All |
18 Years and older (Adult, Senior) |
NCT00777946 |
CSPA100A2303 |
|
October 2008 |
May 2009 |
May 2009 |
October 22, 2008 |
July 12, 2011 |
June 15, 2011 |
- Investigative site
Estonia, Estonia - Investigative site
France, France - Investigative Site
Iceland, Iceland - (and 6 more...)
|
| 50 |
NCT03174002 |
Recruiting |
Handling Oxygenation Targets in the Intensive Care Unit |
- Hypoxemic Respiratory Failure
- Oxygen Toxicity
|
|
Interventional |
Phase 4 |
- Aalborg Universitetshospital
- Rigshospitalet, Denmark
- Copenhagen Trial Unit, Center for Clinical Intervention Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mortality
- Days alive without organ support
- Days alive out of the hospital
- (and 4 more...)
|
2928 |
All |
18 Years and older (Adult, Senior) |
NCT03174002 |
AAUH-ICU-01
2017-000632-34 |
HOT-ICU |
June 19, 2017 |
September 15, 2019 |
June 15, 2020 |
June 2, 2017 |
April 4, 2018 |
|
- Dept. of Intensive Care, Aalborg University Hospital
Aalborg, Denmark - Dept. of Intensive Care, Aarhus University Hospital Nørrebrogade
Aarhus, Denmark - Dept. of Intensive Care, Aarhus University Hospital Tage Hansensgade
Aarhus, Denmark - (and 27 more...)
|
Create an RSS feed from your search for:
Download the search results for: